文献速递银屑病与炎症性皮肤病

甲氨蝶呤与阿达木单抗在中重度银屑病中的真实世界疗效与药物生存对比:BADBIR登记研究

Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
PubMed 文献 · Br J Dermatol · 2023-01-01

该研究基于英国BADBIR登记数据库,纳入2007年9月至2021年12月间首次使用甲氨蝶呤或阿达木单抗且随访≥6个月的中重度银屑病患者,比较真实世界疗效与药物生存。共分析6575例患者,阿达木单抗组达到PASI≤2的比例为77.4%,高于甲氨蝶呤组的37.4%(RR 2.20,95%CI 1.98-2.45)。阿达木单抗组因无效或不良事件导致的停药风险低于甲氨蝶呤组,2年限制性平均生存时间差异为0.53年(95%CI 0.49-0.58)。

要点

  • 阿达木单抗组PASI≤2达标率77.4%,甲氨蝶呤组37.4%,RR 2.20(95%CI 1.98-2.45)。
  • 6、12、24个月时甲氨蝶呤组无效或不良事件相关生存估计均低于阿达木单抗组。
  • 2年限制性平均生存时间差异总体为0.53年(95%CI 0.49-0.58),利于阿达木单抗。

核心结论

  • 真实世界队列中,使用阿达木单抗的患者达到皮损清除或几乎清除的可能性约为甲氨蝶呤的2倍,且因无效或不良事件停药的可能性更低。
  • 该真实世界队列结果为临床医生管理银屑病患者提供了重要信息。

研究设计与样本

  • 研究为基于英国皮肤科医师协会生物制剂与免疫调节剂登记(BADBIR)的队列研究。
  • 纳入标准为2007年9月至2021年12月间注册于BADBIR、年龄≥16岁、首次接受甲氨蝶呤或阿达木单抗治疗且随访≥6个月的患者。
  • 共分析6575例患者,中位年龄44岁,44%为女性;2659例(40.4%)使用甲氨蝶呤,3916例(59.5%)使用阿达木单抗。
  • 疗效定义为治疗开始后≥13周至停药日期间报告的绝对PASI≤2。
  • 采用倾向性评分逆概率治疗加权估计平均治疗效应(ATE),以风险比(RR)表示;采用灵活参数模型估计6、12、24个月时因无效或不良事件停药调整后的标准化平均生存率,并计算2年限制性平均生存时间(RMST)。

主要发现

  • 阿达木单抗组达到PASI≤2的比例为77.4%,甲氨蝶呤组为37.4%;阿达木单抗较甲氨蝶呤更有效(RR 2.20,95%CI 1.98-2.45)。
  • 6个月时因无效或不良事件停药相关生存估计:甲氨蝶呤组69.7(95%CI 67.9-71.5) vs 阿达木单抗组90.6(95%CI 89.8-91.4),甲氨蝶呤组低于阿达木单抗组。
  • 1年时生存估计:甲氨蝶呤组52.5(95%CI 50.4-54.8) vs 阿达木单抗组80.6(95%CI 79.5-81.8),甲氨蝶呤组低于阿达木单抗组。
  • 2年时生存估计:甲氨蝶呤组34.8(95%CI 32.5-37.2) vs 阿达木单抗组68.6(95%CI 67.2-70.0),甲氨蝶呤组低于阿达木单抗组。
  • 2年限制性平均生存时间(年)差异:总体为0.53(95%CI 0.49-0.58),按无效分层为0.37(95%CI 0.33-0.42),按不良事件分层为0.29(95%CI 0.25-0.33)。

关键数值与推荐

  • 疗效标准:治疗开始后≥13周至停药日期间报告的绝对PASI≤2。
  • 平均治疗效应以风险比(RR)表示:阿达木单抗 vs 甲氨蝶呤 RR 2.20(95%CI 1.98-2.45)。
  • 6个月生存估计:甲氨蝶呤组69.7(95%CI 67.9-71.5) vs 阿达木单抗组90.6(95%CI 89.8-91.4)。
  • 1年生存估计:甲氨蝶呤组52.5(95%CI 50.4-54.8) vs 阿达木单抗组80.6(95%CI 79.5-81.8)。
  • 2年生存估计:甲氨蝶呤组34.8(95%CI 32.5-37.2) vs 阿达木单抗组68.6(95%CI 67.2-70.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most information on the comparative effectiveness and survival of methotrexate (MTX) and adalimumab (ADA) in the treatment of psoriasis is from randomized control trials and may not translate to the everyday clinical setting. OBJECTIVES: To determine the real-world effectiveness and survival of MTX and ADA in patients with moderate-to-severe psoriasis registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). METHODS: Eligible patients were registered in BADBIR, ≥ 16 years of age and receiving a first course of MTX or ADA between September 2007 and December 2021, with ≥ 6 months of follow-up. Effectiveness was defined as achieving an absolute Psoriasis Area and Severity Index (PASI) ≤ 2 reported ≥ 13 weeks after the treatment start date until the stop date. The average treatment effect (ATE) was estimated using inverse probability of treatment weighting with propensity score, including baseline covariates. ATE results were presented as risk ratios (RR). A flexible parametric model was used to estimate adjusted standardized average survival, defined as treatment discontinuation associated with ineffectiveness or the occurrence of adverse events (AEs) at 6, 12 and 24 months. Restricted mean survival time (RMST) at 2 years of treatment exposure was calculated. RESULTS: In total, 6575 patients (median age 44 years; 44% female) were analysed; 2659 (40.4%) were prescribed MTX and 3916 (59.5%) ADA. The proportion of patients achieving PASI ≤ 2 was higher in the ADA cohort (77.4%) than in the MTX cohort (37.4%). ADA was more effective than MTX [RR 2.20, 95% confidence interval (CI) 1.98-2.45]. Overall survival associated with ineffectiveness or AEs was lower in the MTX cohort than in the ADA cohort at 6 months [survival estimate 69.7 (95% CI 67.9-71.5) vs. 90.6 (95% CI 89.8-91.4)], 1 year [survival estimate 52.5 (95% CI 50.4-54.8) vs. 80.6 (95% CI 79.5-81.8)] and 2 years [survival estimate 34.8 (95% CI 32.5-37.2) vs. 68.6 (95% CI 67.2-70.0)]. The difference in RMST (years) overall, or when stratified by ineffectiveness and AEs, was 0.53 (95% CI 0.49-0.58), 0.37 (95% CI 0.33-0.42) and 0.29 (95% CI 0.25-0.33), respectively. CONCLUSIONS: Patients on ADA were twice as likely to be clear or nearly clear of psoriasis and were less likely to discontinue their medication than patients on MTX. Findings from this real-world cohort provide important information to aid clinicians managing patients with psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Alabas OA, Mason KJ, Yiu ZZN, et al. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2023. PMID: 37226927. doi:10.1093/bjd/ljad179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。